News
NERV
2.580
+3.20%
0.080
Weekly Report: what happened at NERV last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at NERV last week (0311-0315)?
Weekly Report · 03/18 11:52
Weekly Report: what happened at NERV last week (0304-0308)?
Weekly Report · 03/11 11:48
Weekly Report: what happened at NERV last week (0226-0301)?
Weekly Report · 03/04 11:51
Dow Dips Over 100 Points; J.M. Smucker Posts Upbeat Earnings
The Dow Jones index fell more than 100 points on Tuesday. The Dow traded down 0.35% to 38,932.26 while the NASDAQ rose 0.28%. J.M. Smucker Company posted better-than-expected earnings for its fourth quarter. Utilities shares rose by 1.2% on Tuesday as energy shares fell by 0.4%. Asian markets closed higher on Tuesday while European shares closed mixed.
Benzinga · 02/27 19:32
BUZZ-U.S. STOCKS ON THE MOVE-Cava, Bank of America, Fractyl Health
Wall Street's main indexes were mixed on Tuesday. The Dow Jones Industrial Average was down 0.41% at 38,910.21. Norwegian Cruise Line Holdings was one of the top percentage gainers on the S&P 500. Investors are awaiting a crucial inflation report and other economic data.
Reuters · 02/27 19:24
Health Care Sector Update for 02/27/2024: VKTX, CAPR, NERV
NASDAQ · 02/27 18:51
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Helix Energy Solutions Group, Inc. Shares dipped 11% to $9.13 on Tuesday. The company posted weak earnings of 6 cents per share. Janux Therapeutics shares jumped 145% after the company announced updated clinical data for both of its clinical programs. Other stocks moving in Tuesday's mid-day session included Viking Therapeutic and Presto Automation.
Benzinga · 02/27 18:18
Regulatory Setback For Minerva Neurosciences' Schizophrenia Treatment Candidate, FDA Asks For More Data
FDA issued a Complete Response Letter to Minerva Neurosciences Inc's marketing application for roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company's shares are trading lower after the FDA issued the CRL. The FDA cited the company's application lacks clinical deficiencies.
Benzinga · 02/27 17:53
BBAI, CTMX and STRC among mid-day movers
On the Move BBAI, CTMX and STRC among mid-day movers. Janux Therapeutics and BigBear.ai Holdings were among the biggest gainers. Minerva Neurosciences was among the companies that lost ground in the biotech sector.
Seeking Alpha · 02/27 17:52
Minerva Neurosciences Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Dow Jones · 02/27 17:45
HC Wainwright & Co. Reiterates Neutral on Minerva Neurosciences, Maintains $11 Price Target
Benzinga · 02/27 17:35
12 Health Care Stocks Moving In Tuesday's Intraday Session
Janux Therapeutics (NASDAQ:JANX) stock increased by 189.9% to $43.78 during Tuesday's regular session. The company's market cap stands at $2.0 billion. Viking Therapeutic shares moved upwards by 91.96% as the company's Q4 earnings report came out.
Benzinga · 02/27 17:31
Crude Oil Gains 1%; Macy's Plans To Close 150 Stores
The Dow Jones index fell around 150 points on Tuesday. Macy’s reported mixed quarterly results and announced plans to close 150 stores. Utilities shares rose by 1.5% on Tuesday; energy shares fell by 0.5%. Asian markets closed higher on Tuesday as European shares were mostly higher.
Benzinga · 02/27 17:24
Hold Rating on Minerva Neurosciences Amid FDA Setbacks and Financial Constraints
TipRanks · 02/27 16:05
BUZZ-U.S. STOCKS ON THE MOVE-Kroger, Sezzle, Sealed Air Corp
The Dow Jones Industrial Average was down 0.31% on Tuesday. Norwegian Cruise Line Holdings was the biggest percentage gainer on the S&P 500. McDonald's and Sealed Air Corp were among the biggest losers on the NYSE. The Dow led Wall Street lower on Tuesday as investors awaited a crucial inflation report.
Reuters · 02/27 16:02
Minerva Neurosciences Shares Slide on Latest FDA Roluperidone Setback
Minerva Neurosciences shares lost more than half of their value in early trading. The company was seeking approval of its lead drug candidate for schizophrenia treatment. The FDA turned away the company's application for the drug in 2022. Minerva says the FDA raised numerous issues with the application. Shares of the company were down 57%.
Dow Jones · 02/27 15:02
Nasdaq Rises 50 Points; Lowe's Earnings Top Views
U.S. Stocks traded mixed on Tuesday, with the Nasdaq Composite gaining around 50 points. The Dow traded down 0.07% to 39,043.13 while the NASDAQ rose 0.31%. Lowe's Companies Inc posted better-than-expected fourth-quarter results. Utilities shares rose by 0.7% on Tuesday; health care shares fell 0.3%. Asian markets closed higher in Asia markets.
Benzinga · 02/27 14:42
BUZZ-U.S. STOCKS ON THE MOVE-Intuitive Machines, Hims & Hers Health, Macy's
Wall Street was set for a subdued open on Tuesday. Dow e-minis were down 0.08% and S&P 500 and Nasdaq 100 up 0.21%. Intuitive Machines, Hims & Hers Health, Macy's among top NYSE percentage gainers.
Reuters · 02/27 14:24
BUZZ-Minerva Neurosciences slumps as FDA declines to approve schizophrenia drug
Minerva Neurosciences slumps about 64.7% to $2.40 in premarket trading. Company says U.S. FDA declines to approve its schizophrenia drug. The drug regulates behavioral changes in patients with schizophrenia that can cause social withdrawal and lack of motivation.
Reuters · 02/27 13:55
More
Webull provides a variety of real-time NERV stock news. You can receive the latest news about Minerva Neurosci through multiple platforms. This information may help you make smarter investment decisions.
About NERV
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's lead product candidates are roluperidone (MIN-101) and MIN-301. Roluperidone (MIN-101) is a compound that blocks serotonin, sigma, and α adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. The Company is developing roluperidone to treat patients with schizophrenia. Roluperidone is designed to block a specific subtype of serotonin receptor called 5-HT2A. The Company’s MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson’s disease and for other neurodegenerative disorders. The Company is also developing seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD).